{
  "docId": "019de073-3cb6-7521-8cc2-fe64231d84c9",
  "docSlug": "d538949ee3add2afed287b359e626655",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 25 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 25,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/8",
  "deckHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9",
  "deckJsonHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json",
  "deckAnchorHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.68,
        "x": 0.28,
        "y": 0.84
      },
      "kind": "disclaimer",
      "text": "1. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36(1):13-34; www.bacterio.net/mycobacterium.\n2. Nontuberculous Mycobacteria (NTM) Infections, Healthcare-Associated Infections, Centers for Disease Control webpage (last updated August 12, 2019).\n3. Nontuberculous Mycobacteria Lung Disease, Rare Disease Database, National Organization for Rare Disorders webpage (last updated 2018).\n4. Who Is At Risk? About NTM Fact Page, Insmed webpage.\n5. Diel R, et al. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. BMC Infect Dis. 2018;18(1):206. Published 2018 May 3.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e015a34b-7bcc-41cc-b0e3-157adc929535",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.68,
        "x": 0.28,
        "y": 0.08
      },
      "kind": "list",
      "text": "NTM is a group of >200 species of mycobacteria commonly found in water and soil; unlike tuberculosis, not transmitted person-to-person\nEpetaborole is being developed for the most common type of NTM, Mycobacterium avium complex (MAC)\nMAC causes ~80% of cases of NTM lung disease\nSymptoms similar to those associated with other chronic respiratory diseases\nCauses chronic infection that progresses to fibrosis, permanent lung damage and respiratory failure\nWomen and 65+ age group most affected\n5-year mortality rate between 10-48%",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ead048a9-9533-49f2-9b15-4b8529c153da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.22,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "NTM lung disease a rare, chronic and progressive infectious disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e07975e6-76b1-4d77-98cf-a91a8648ee75",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 8,
      "beatId": "3c9832b8-bfc2-4ca8-ad8d-8f1231fddb47",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slides 8-10 present the problem statement, market sizing, and current treatment regimens",
      "position": 0,
      "confidence": 0.9,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "13b74b4b-a68a-4f96-aedb-d9fa2b458a5f",
      "evidence": "The problem statement and market sizing slides imply the cost of inaction",
      "position": 0,
      "objective": "What is the cost of not addressing NTM lung disease?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}